FAR2
Fatty acyl-CoA reductase 2
Also known as: FACR2_HUMAN, FLJ10462, MLSTD1, SDR10E2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96K12
- Gene
- FAR2
- Ensembl
- ENSG00000064763
- Chromosome
- 12
- Canonical length
- 515 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Nucleoli,Golgi apparatus
OverviewNCBI Gene
This gene belongs to the short chain dehydrogenase/reductase superfamily. It encodes a reductase enzyme involved in the first step of wax biosynthesis wherein fatty acids are converted to fatty alcohols. The encoded peroxisomal protein utilizes saturated fatty acids of 16 or 18 carbons as preferred substrates. Alternatively spliced transcript variants have been observed for this gene. Related pseudogenes have been identified on chromosomes 2, 14 and 22. [provided by RefSeq, Nov 2012]
Canonical amino-acid sequenceUniProt
515 residues, UniProt reviewed canonical sequence.
>Q96K12|FAR2
1 MSTIAAFYGG KSILITGATG FLGKVLMEKL FRTSPDLKVI YILVRPKAGQ TLQQRVFQIL
61 DSKLFEKVKE VCPNVHEKIR AIYADLNQND FAISKEDMQE LLSCTNIIFH CAATVRFDDT
121 LRHAVQLNVT ATRQLLLMAS QMPKLEAFIH ISTAYSNCNL KHIDEVIYPC PVEPKKIIDS
181 LEWLDDAIID EITPKLIRDW PNIYTYTKAL GEMVVQQESR NLNIAIIRPS IVGATWQEPF
241 PGWVDNINGP NGIIIATGKG FLRAIKATPM AVADVIPVDT VVNLMLAVGW YTAVHRPKST
301 LVYHITSGNM NPCNWHKMGV QVLATFEKIP FERPFRRPNA NFTSNSFTSQ YWNAVSHRAP
361 AIIYDCYLRL TGRKPRMTKL MNRLLRTVSM LEYFINRSWE WSTYNTEMLM SELSPEDQRV
421 FNFDVRQLNW LEYIENYVLG VKKYLLKEDM AGIPKAKQRL KRLRNIHYLF NTALFLIAWR
481 LLIARSQMAR NVWFFIVSFC YKFLSYFRAS STLKVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FAR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 21 nTPM
Expression across tissuesHPA
Tissue
- colon: 21 nTPM
- rectum: 21 nTPM
- epididymis: 18 nTPM
- placenta: 12 nTPM
- small intestine: 12 nTPM
- bone marrow: 10 nTPM
Single-cell type
- neutrophil progenitors: 904 nCPM
- cardiomyocytes: 714 nCPM
- syncytiotrophoblasts: 641 nCPM
- neutrophils: 524 nCPM
- microglia: 267 nCPM
- megakaryocyte progenitors: 195 nCPM
Immune cell
- eosinophil: 39 nTPM
- neutrophil: 23 nTPM
- classical monocyte: 16 nTPM
- intermediate monocyte: 9.4 nTPM
- T-reg: 9.2 nTPM
- total PBMC: 5.6 nTPM
Brain region
- hypothalamus: 10 nTPM
- basal ganglia: 8.4 nTPM
- cerebral cortex: 7.3 nTPM
- hippocampal formation: 6.2 nTPM
- thalamus: 5.6 nTPM
- white matter: 5.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FAR2.
Disease | ImmuneIEDB
Conditions an epitope on FAR2 was assayed in.
- viral infectious disease T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.43
- gnomAD pLI
- 0.56
- gnomAD missense Z
- 1.7
- DepMap mean gene effect
- -0.26
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- alcohol-forming long-chain fatty acyl-CoA reductase activity
- alcohol-forming very long-chain fatty acyl-CoA reductase activity
- oxidoreductase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FAR2 as an antibody target. Whether an autoantibody or antibody against FAR2 could matter depends on whether native FAR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FAR2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FAR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...